Queensland, Australia - 29 October 2014 - Johnson & Johnson Innovation today announced the opening of the Asia Pacific Innovation Center, located in Shanghai with satellites in Singapore, Australia and Japan. With local science and technology experts and deal-making capabilities, the Center will identify and develop promising early-stage opportunities across the Company’s three areas of focus: Pharmaceuticals, Medical Devices and Diagnostics and Consumer healthcare products. To date, the Innovation Centers have established more than 80 collaborations, including six announced today with organizations in Australia and China.
“We are excited to launch the Asia Pacific Innovation Center which builds on the momentum of our Centers in London, California and Boston. Our goal is to collaborate with the best minds in the region to advance new technologies and deliver transformative solutions for the people of China and Asia Pacific at large, and throughout the world,” said Paul Stoffels, MD., Johnson & Johnson Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals.
Dong Wu, Head of the Johnson & Johnson Innovation Asia Pacific Innovation Center, said, “There is an explosion of growth in the Asia Pacific region, and China in particular, as well as significant medical needs. The Asia Pacific Innovation Center plans to build on the Company’s track record of collaboration in the region and advance the most promising science. It will play a key role in sourcing early stage science in the region for the development of new medicines, medical devices, and consumer products.”
The Asia Pacific Innovation Center is part of Johnson & Johnson Innovation, a division of Johnson & Johnson (China) Investment Ltd. Johnson & Johnson Innovation focuses on accelerating early-stage innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses.